Doctors at Georgetown University in Washington D.C. say that changes to the microbiome and a fungus in the tumors of young patients could be behind a higher risk of developing colon cancer.
Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.